INSM Insmed Inc

$174.09

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Insmed's upcoming earnings report, set for October 23, 2025, arrives at a pivotal moment as the company continues to navigate the competitive landscape of biopharmaceuticals with a market cap of approximately $34.3 billion. Analysts are projecting an EPS of $0.00, aligning with the whisper number, which suggests that expectations are tempered for this quarter. Revenue is anticipated to reach $114.87 million, a figure that will be closely scrutinized for signs of growth or stability in the company's product pipeline. Despite the absence of recent news, investors will be keen to see how Insmed's strategic initiatives and potential advancements in its therapeutic offerings might influence future earnings. This earnings release will serve as a crucial indicator of Insmed's ability to maintain momentum in a challenging market environment.

Updated On 1/6/2026

About Insmed Inc

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Website: https://www.insmed.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1104506
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ, US
Valuation
Market Cap
$13.20B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
46.29
Performance
EPS
$-5.57
Dividend Yield
—
Profit Margin
-251.20%
ROE
-891.00%
Technicals
50D MA
$76.03
200D MA
$73.81
52W High
$84.91
52W Low
$21.92
Fundamentals
Shares Outstanding
182M
Target Price
$97.24
Beta
1.07

INSM EPS Estimates vs Actual

● Estimated
● Actual

INSM News & Sentiment

Dec 30, 2025 • FinancialContent BEARISH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (NASDAQ: INSM) following a significant stock price drop. This investigation comes after Insmed announced that its Phase 2b BiRCh study of brensocatib failed to meet its primary or secondary efficacy endpoints, leading to the discontinuation of the drug's development. Investors are advised to contact Danielle Peyton regarding potential securities fraud or unlawful business practices.
Dec 30, 2025 • Business Wire BEARISH
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Insmed Incorporated (NASDAQ: INSM) on behalf of investors for potential securities law violations. This investigation follows Insmed's announcement on December 17, 2025, that its Phase 2b BiRCh study for brensocatib in chronic rhinosinusitis without nasal polyps failed to meet efficacy endpoints, leading to a significant 16.1% drop in stock value the next day. Shareholders who suffered losses are encouraged to contact the firm to discuss their rights.
Dec 29, 2025 • WCIA.com BEARISH
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Insmed Incorporated (INSM) stockholders following a significant stock price drop. The drop occurred after Insmed announced that its Phase 2b BiRCh study for brensocatib failed to meet its primary or secondary efficacy endpoints, leading to the discontinuation of the drug's development. The firm is encouraging affected investors to inquire about participation in the securities investigation.
Dec 29, 2025 • WFXR News BEARISH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
Pomerantz LLP is investigating potential claims against Insmed Incorporated (NASDAQ: INSM) on behalf of its investors. This investigation follows a significant drop in Insmed's stock price after its Phase 2b BiRCh study for brensocatib failed to meet its primary or secondary efficacy endpoints, leading the company to discontinue the drug's development. Investors are advised to contact Pomerantz LLP for more information regarding this potential securities fraud inquiry.
Dec 29, 2025 • WRIC ABC 8News BEARISH
Insmed Incorporated (INSM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Insmed Incorporated (NASDAQ: INSM) on behalf of investors. This investigation follows a significant drop in Insmed's stock price after the company announced that a Phase 2b study for brensocatib failed to meet its primary and secondary efficacy endpoints, leading to the discontinuation of the drug's development. Stockholders who purchased Insmed securities are encouraged to contact the firm for more information regarding this investigation.
Dec 28, 2025 • Eyewitness News (WEHT/WTVW) BEARISH
Insmed Incorporated (INSM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Insmed Incorporated (INSM) following a significant stock price drop. This drop occurred after Insmed announced that its Phase 2b BiRCh study for brensocatib failed to meet its primary or secondary efficacy endpoints, leading to the discontinuation of the drug's development. The firm is encouraging stockholders who purchased Insmed securities to contact them to learn more about the investigation and assist with potential class action claims.
Sentiment Snapshot

Average Sentiment Score:

-0.382
50 articles with scored sentiment

Overall Sentiment:

Bearish

INSM Reported Earnings

Aug 07, 2025
Jun 30, 2025 (Pre market)
-0.4 Surprise
  • Reported EPS: $-1.70
  • Estimate: $-1.30
  • Whisper: —
  • Surprise %: -30.8%
May 08, 2025
Mar 31, 2025 (Pre market)
-0.22 Surprise
  • Reported EPS: $-1.42
  • Estimate: $-1.20
  • Whisper: —
  • Surprise %: -18.3%
Feb 20, 2025
Dec 31, 2024 (Pre market)
-0.09 Surprise
  • Reported EPS: $-1.32
  • Estimate: $-1.23
  • Whisper: —
  • Surprise %: -7.3%
Oct 31, 2024
Sep 30, 2024 (Pre market)
-0.05 Surprise
  • Reported EPS: $-1.27
  • Estimate: $-1.22
  • Whisper: —
  • Surprise %: -4.1%
Aug 08, 2024
Jun 30, 2024 (Pre market)
-0.67 Surprise
  • Reported EPS: $-1.94
  • Estimate: $-1.27
  • Whisper: —
  • Surprise %: -52.8%
May 09, 2024
Mar 31, 2024 (Pre market)
0.17 Surprise
  • Reported EPS: $-1.06
  • Estimate: $-1.23
  • Whisper: —
  • Surprise %: 13.8%
Feb 22, 2024
Dec 31, 2023 (Pre market)
-0.13 Surprise
  • Reported EPS: $-1.28
  • Estimate: $-1.15
  • Whisper: —
  • Surprise %: -11.3%
Oct 26, 2023
Sep 30, 2023 (Pre market)
0.02 Surprise
  • Reported EPS: $-1.11
  • Estimate: $-1.13
  • Whisper: —
  • Surprise %: 1.8%
Aug 03, 2023
Jun 30, 2023 (Pre market)
-0.65 Surprise
  • Reported EPS: $-1.78
  • Estimate: $-1.13
  • Whisper: —
  • Surprise %: -57.5%

Financials